Treatment of patients with recurrence or who do not respond to the first treatment against hepatitis C
The current criteria to confirm the absence of therapeutic response to HCV is based on the viral findings. Lack of response is defined as the failure to achieve a negative serological response to the virus in peripheral blood (serum or plasma) after 12 weeks of treatment with interferon alpha (2a or...
Saved in:
Published in: | Revista de gastroenterología de México Vol. 67 Suppl 2; pp. S45 - S48 |
---|---|
Main Author: | |
Format: | Journal Article |
Language: | Spanish |
Published: |
Mexico
01-10-2002
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | The current criteria to confirm the absence of therapeutic response to HCV is based on the viral findings. Lack of response is defined as the failure to achieve a negative serological response to the virus in peripheral blood (serum or plasma) after 12 weeks of treatment with interferon alpha (2a or 2b), or 24 weeks of treatment with IFN and ribavirin. Up to 60% of patients treated with standard IFN alpha and ribavirin are considered non-responders. According to viral genotype, figures are still worse in the group with genotype 1. Recently, the use of pegylated interferon allowed the reduction of the number of non-responding patients. The investigators propose different approaches in the search for better therapeutic strategies. The most effective of them all are the addition of ribavirin to the therapeutic scheme and the use of pegylated interferon which greatly increased the number of responders. Nevertheless, there are still many patients who are resistant to therapy. These are the proposed therapeutic alternatives for non-respondent patients: 1. Another tretment cycle with standard IFN and ribavirin (low probability) 2. Another treatment cycle with pegylated IFN and ribavirin. 3. Another treatment cycle with IFN, ribavirin and amantadine. 4. Another treatment cycle with IFN, ribavirin and timosine. 5. Other antiviral agents. It's important to clarify that "real non-responders" are those patients who remain positive in the viral load tests after 12-24 months of treatment. On the other hand, patients who "escape from treatment" or those with "recurrence" are not real non-responders, compared to those who are negative after 12-24 weeks of treatment. |
---|---|
AbstractList | The current criteria to confirm the absence of therapeutic response to HCV is based on the viral findings. Lack of response is defined as the failure to achieve a negative serological response to the virus in peripheral blood (serum or plasma) after 12 weeks of treatment with interferon alpha (2a or 2b), or 24 weeks of treatment with IFN and ribavirin. Up to 60% of patients treated with standard IFN alpha and ribavirin are considered non-responders. According to viral genotype, figures are still worse in the group with genotype 1. Recently, the use of pegylated interferon allowed the reduction of the number of non-responding patients. The investigators propose different approaches in the search for better therapeutic strategies. The most effective of them all are the addition of ribavirin to the therapeutic scheme and the use of pegylated interferon which greatly increased the number of responders. Nevertheless, there are still many patients who are resistant to therapy. These are the proposed therapeutic alternatives for non-respondent patients: 1. Another tretment cycle with standard IFN and ribavirin (low probability) 2. Another treatment cycle with pegylated IFN and ribavirin. 3. Another treatment cycle with IFN, ribavirin and amantadine. 4. Another treatment cycle with IFN, ribavirin and timosine. 5. Other antiviral agents. It's important to clarify that "real non-responders" are those patients who remain positive in the viral load tests after 12-24 months of treatment. On the other hand, patients who "escape from treatment" or those with "recurrence" are not real non-responders, compared to those who are negative after 12-24 weeks of treatment. |
Author | Poo, Jorge Luis |
Author_xml | – sequence: 1 givenname: Jorge Luis surname: Poo fullname: Poo, Jorge Luis email: jpoo@medicasur.org.mx organization: Dirección del Centro de Investigación Farmacológica y Biotecnología, Fundación Clínica Médica Sur. Puente de Piedra # 150, Col. Toriello Guerra, Deleg. Tlalpan. jpoo@medicasur.org.mx |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12712853$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kE1LxDAYhHNYcT_0L0hO3gppsmmSoyx-wYKX3sub9q2NbJOapCz-eyuunmaYGZ7DbMnKB48rsmFCyYIZVq3JNqUPxlilGb8m65KrkmspNqSvI0Ie0WcaejpBdotN9OzyQCO2c4zoW6Qh0vMQaBeoD3kp0hR8R3OgeUDau5gyzf8geAfnl2TAH152iR5uyFUPp4S3F92R-umxPrwUx7fn18PDsZjkXhTG9GANSAEMjQC5L7W1wlqA1nYl00pqI5VlVWmqVgio0FrkolISVM94K3bk_hc7xfA5Y8rN6FKLpxN4DHNqFNd6rxVfhneX4WxH7JopuhHiV_N3jPgGH_VhfA |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Tratamiento de los pacientes con recaída o que no responden al primer tratamiento contra el virus de la hepatitis C |
EndPage | S48 |
ExternalDocumentID | 12712853 |
Genre | English Abstract Journal Article Review |
GroupedDBID | 0R~ 0SF 457 65R 6I. 77H AACTN AAEDW AAFTH AALRI AAXUO ABMAC ACGFS ADBBV ADCUG ADEZE ADVLN AEVXI AEXQZ AFTJW AGHFR AITUG ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BCNDV CGR CUY CVF DIK EBS ECM EIF EJD F5P FDB FRP GROUPED_DOAJ GX1 IPNFZ KQ8 NCXOZ NPM O9- OK1 RIG ROL SSZ W2D 7X8 |
ID | FETCH-LOGICAL-p543-99fab9a53a0e93a5418bb3bbaacbd108758957b06196c33a6ebbe23675a7f02c3 |
ISSN | 0375-0906 |
IngestDate | Thu Apr 11 19:30:27 EDT 2024 Sat Sep 28 07:47:41 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Language | Spanish |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p543-99fab9a53a0e93a5418bb3bbaacbd108758957b06196c33a6ebbe23675a7f02c3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 |
PMID | 12712853 |
PQID | 72884872 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_72884872 pubmed_primary_12712853 |
PublicationCentury | 2000 |
PublicationDate | 2002-Oct 20021001 |
PublicationDateYYYYMMDD | 2002-10-01 |
PublicationDate_xml | – month: 10 year: 2002 text: 2002-Oct |
PublicationDecade | 2000 |
PublicationPlace | Mexico |
PublicationPlace_xml | – name: Mexico |
PublicationTitle | Revista de gastroenterología de México |
PublicationTitleAlternate | Rev Gastroenterol Mex |
PublicationYear | 2002 |
SSID | ssj0006802 |
Score | 1.5663699 |
SecondaryResourceType | review_article |
Snippet | The current criteria to confirm the absence of therapeutic response to HCV is based on the viral findings. Lack of response is defined as the failure to... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | S45 |
SubjectTerms | Antiviral Agents - therapeutic use Hepatitis C - drug therapy Humans Interferons - therapeutic use Recurrence Ribavirin - therapeutic use |
Title | Treatment of patients with recurrence or who do not respond to the first treatment against hepatitis C |
URI | https://www.ncbi.nlm.nih.gov/pubmed/12712853 https://search.proquest.com/docview/72884872 |
Volume | 67 Suppl 2 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ3Nb9MwFMAtugPigvhmbMA7cIsipXEc20e0dgLRjUODtFtkx87opZ6SVPDn8xy7aXdAwIGLFTlKIvkXPT-_T0I-tKywtrU85dIWPiUnS4XkNG3yhgnaGNxlxia2a359IxbLYnnozXeY-6-kcQ5Z-8zZf6A9vRQn8BqZ44jUcfw77lPkuI9lDlVTYwpb523roaqs65If311iXLJ1A97wgbJmr4e2G1QJj0PQb9UGtUhUKv37hk0fTav7ut4-QX1QibHJreqHzvkyn50XqqMXfjHeuQoe-Z_4403S2AWvjzfKJ6vd5r4FIp9i2abMK868vac8lqolT8a-pEl-JB7XoXRk3GnXocbm_SLY11_ry2-rVV0tb6oZmdG5j9NcfP4yba-lyIJrKH7090eDUUWonpDHUbeHjwHKU_LA9s_Iw6sYvfCctBMbcC3s2YBnAwc24DpANmAcIBuIbGBwgGxgZAMTG4hsYGIDFy9IdbmsLj6lsc9Fesd87INslZaKUZVZSRUr5kJrqrVSjTZz33FASMY1Kl6ybChVpdXa-sJ7TPE2yxv6kpxs3da-JsCbsigljpmkhdFWCdO0hSnxzKipteKUvN-vVY1ixPuG1Na6XV_zXAg8u-an5FVYwvouVDup5zlHHYbRN3989ow8Ovwe5-Rk6Hb2LZn1ZvduRPgLj51Llw |
link.rule.ids | 315,782,786 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+patients+with+recurrence+or+who+do+not+respond+to+the+first+treatment+against+hepatitis+C&rft.jtitle=Revista+de+gastroenterolog%C3%ADa+de+M%C3%A9xico&rft.au=Poo%2C+Jorge+Luis&rft.date=2002-10-01&rft.issn=0375-0906&rft.volume=67+Suppl+2&rft.spage=S45&rft.epage=S48&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0375-0906&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0375-0906&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0375-0906&client=summon |